About
Profile
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
FRTX
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Fresh Tracks Therapeutics to hold new stockholders meeting to seek liquidation approval
- Fresh Tracks Therapeutics common stock to be suspended from trading on Nasdaq at open of business on Dec 19
- Fresh Tracks Therapeutics GAAP EPS of $0.32, revenue of $7.94M
- Fresh Track Therapeutics board approves plan to liquidate company
- Fresh Tracks Therapeutics GAAP EPS of -$0.39, revenue of $0.05M
- Fresh Tracks enters amendment to asset purchase agreement with Botanix
- Fresh Tracks Therapeutics GAAP EPS of -$1.14
- Fresh Tracks Therapeutics GAAP EPS of -$1.50, revenue of $2.05M
- Fresh Tracks stock soars ~75% as eczema drug shows promise in trial; eyes strategic options
- Fresh Tracks Therapeutics names Andrew Sklawer as CEO
- Fresh Tracks Therapeutics reports GAAP EPS of -$2.07, revenue of $0.49M
- Q3 2022 Earnings Preview
- Brickell Biotech changes name to Fresh Tracks Therapeutics
- Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M
- Brickell Biotech Q2 2022 Earnings Preview
- Brickell Biotech regains Nasdaq compliance for minimum bid price requirement
- Brickell Biotech announces 1-for-45 reverse stock split
- Brickell Biotech begins dosing in phase 1 trial of oral drug BBI-02 for eczema
- Brickell Biotech GAAP EPS of -$0.08 misses by $0.02, revenue of $0.09M misses by $0.05M
- Brickell Biotech Q1 2022 Earnings Preview